Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
The company also agreed to pay $70 million to settle a whistleblower lawsuit
GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional $70 million set aside for a qui tam case. The company maintains there is no evidence linking ranitidine to cancer risks.
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
Zantac maker GSK says it reaches $2.3 bn settlement in US
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.
GSK reaches $2.2bn heartburn medication Zantac settlement in US
GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK to Settle 80,000 Zantac Cases for Up to $2.2 Billion
GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.
TOP NEWS: GSK to settle 80,000 Zantac cases for up to USD2.2 billion
(Alliance News) - GSK PLC on Wednesday agreed to pay up to USD2.2 billion to settle the vast majority of cases linked to its heartburn medicine Zantac.
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
49m
on MSN
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
Thanks largely to news of a crucial legal settlement, GSK (NYSE: GSK) was one of the better-performing big pharma stocks on ...
Medpage Today on MSN
2d
Acne Treatments Taken Right Off the Shelf Had High Levels of Benzene
Dozens of over-the-counter acne products had very high levels of the known carcinogen benzene, even when they were taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Reveals breast cancer battle
Approves elimination of NLI
Proposes new Medicare plan
‘Risky Business' actor dies
Pilot's death forces landing
Increases heart attack risk?
Tropicana casino implosion
273 'noncitizens' removed
$250M to women's health
GA regents ask for trans ban
Fat Bear Week winner
SCOTUS hears appeal
Former Sen. Johnson dies
3% HS students transgender
Monet painting returned
Georgia election board sued
$2 Medicare drugs list
Postpones NJ concert
Speaks with Netanyahu
Recalls about 1.7M vehicles
Report on election meddling
Small business loan crisis
New trial date set
Campaign, groups raise $1B
Early voting begins in AZ
Philly refinery settlement
Palestinian death toll
Ukraine meeting postponed
Antitrust case update
Related topics
Zantac
GSK
GlaxoSmithKline
Feedback